RM has received honoraria from Sanofi, Pfizer, Amgen, Takeda, Celgene, Janssen; has served on the advisory boards for Bristol Myers Squibb, Amgen, Takeda, Celgene, Janssen; has received consultancy fees from Sanofi, Takeda. FG has received honoraria from AbbVie, Roche, Takeda, Pfizer, Sanofi, Celgene/Bristol Myers Squibb, Janssen, GlaxoSmithKline; has served on advisory board for Abbvie, Roche, Takeda, Pfizer, Sanofi, Celgene/Bristol Myers Squibb, Oncopeptides, Janssen¸ GlaxoSmithKline. MD has received honoraria from GlaxoSmithKline, Sanofi, and Janssen; has served on the advisory boards for GlaxoSmithKline, Sanofi, Adaptive Biotechnologies, and Bristol Myers Squibb. SO has received honoraria from Abbvie, Takeda, Celgene/Bristol Myers Squibb, Amgen; has received consultancy fees from Janssen, Amgen, Adaptive Biotechnologies. AL has received honoraria from Janssen, GlaxoSmithKline, Menarini, Pfizer, Sanofi; has served on the advisory board for Janssen, GlaxoSmithKline, Menarini, Pfizer, Sanofi. GB has received honoraria from Bristol Myers Squibb, Janssen, Novartis, Jansen; has received consultancy fees from Bristol Myers Squibb, Janssen, Novartis. BB has received honoraria from Amgen, Janssen, Novartis, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Jazz Pharmaceuticals, AstraZeneca, Incyte; has served on advisory boards for Amgen, Jazz Pharmaceuticals. AS has received honoraria from Eisai, Pfizer, Gilead, Servier, Celgene/Bristol Myers Squibb, Bayer, Merck MSD, Roche, Abbvie, Amgen; AstraZeneca; Eli Lilly; Sandoz; Novartis; has served on the advisory board for Eisa, Pfizer, Gilead, Servier, Bristol Myers Squibb, Bayer, Merck MSD; has received consultancy fees from Incyte, Sanofi. SB has received honoraria from Celgene, Amgen, Janssen, Bristol Myers Squibb; has served on the board of directors or advisory committees for Celgene, Amgen, Janssen, GlaxoSmithKline, Sanofi, Pfizer; has received consultancy fees from Janssen, Takeda, Celgene, Bristol Myers Squibb. The other authors have nothing to declare.

This study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee or institutional review boards at each of the participating centers (Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and IRCCS Humanitas Research Hospital). All participants were provided with comprehensive information about the study. Written informed consent was obtained from all participants prior to their inclusion in the study. Personal data were collected and stored in a secure and anonymized manner to ensure participants’ confidentiality and privacy.